Cargando…

Shifting the focus – the primary role of IL‐23 in psoriasis and other inflammatory disorders

Insights into the pathophysiology of autoimmune inflammatory diseases including psoriasis have advanced considerably in recent years, and in parallel, so too have the available treatment options. Current clinical paradigms for the treatment of psoriasis have evolved to include targeted biologic ther...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gooderham, M.J., Papp, K.A., Lynde, C.W.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2018
Materias:	Review Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6033004/ https://www.ncbi.nlm.nih.gov/pubmed/29438576 http://dx.doi.org/10.1111/jdv.14868

Ejemplares similares

Treatment satisfaction, safety and effectiveness of adding methotrexate to adalimumab in patients with psoriasis responding suboptimally to adalimumab in a real‐world setting
por: Papp, K.A., et al.
Publicado: (2022)

Selective Phosphodiesterase Inhibitors for Psoriasis: Focus on Apremilast
por: Gooderham, Melinda, et al.
Publicado: (2015)

A Review of the Efficacy and Safety for Biologic Agents Targeting IL-23 in Treating Psoriasis With the Focus on Tildrakizumab
por: Ghazawi, Feras M., et al.
Publicado: (2021)

Real‐world, long‐term treatment patterns of commonly used biologics in Canadian patients with moderate‐to‐severe chronic plaque psoriasis
por: Gooderham, Melinda J., et al.
Publicado: (2021)

Phase I randomized study of KHK4083, an anti‐OX40 monoclonal antibody, in patients with mild to moderate plaque psoriasis
por: Papp, K.A., et al.
Publicado: (2017)

The role of IL-23 in the immunopathogenesis of psoriasis
por: Meglio, Paola Di, et al.
Publicado: (2010)

Emerging paradigm shift toward proactive topical treatment of psoriasis: A narrative review
por: Papp, Kim A., et al.
Publicado: (2021)

Psoriasis Prevalence and Severity by Expert Elicitation
por: Papp, Kim A., et al.
Publicado: (2021)

35158 Adaptations in the PURE registry in response to the COVID 19 pandemic: The impact of well-designed modifications in real-world data collection in a psoriasis registry
por: Lynde, Charles, et al.
Publicado: (2022)

Improvements in patient‐reported outcomes in patients with psoriasis receiving etanercept plus topical therapies: results from REFINE
por: Papp, K.A., et al.
Publicado: (2015)

The role of IL‐23 and the IL‐23/T(H)17 immune axis in the pathogenesis and treatment of psoriasis
por: Girolomoni, G., et al.
Publicado: (2017)

Safety of Adalimumab Dosed Every Week and Every Other Week: Focus on Patients with Hidradenitis Suppurativa or Psoriasis
por: Ryan, Caitriona, et al.
Publicado: (2018)

Practical and Relevant Guidelines for the Management of Psoriasis: An Inference-Based Methodology
por: Papp, Kim A., et al.
Publicado: (2021)

Targeting IL-23 in psoriasis: current perspectives
por: Fotiadou, Christina, et al.
Publicado: (2018)

Sustained Effectiveness of Secukinumab Across Different Body Regions in Patients with Moderate-to-Severe Plaque Psoriasis from the PURE Registry
por: Gooderham, Melinda, et al.
Publicado: (2022)

Adaptive and Innate Immunity in Psoriasis and Other Inflammatory Disorders
por: Schön, Michael P.
Publicado: (2019)

A Randomized, blinded assessor study to Evaluate the efFIcacy and safety of etanercept 50 mg once weekly plus as Needed topical agent vs. Etanercept 50 mg twice weekly in patients with moderate to severe plaque psoriasis (REFINE)
por: Papp, KA, et al.
Publicado: (2015)

TARGETING IL-23: INSIGHTS INTO THE PATHOGENESIS AND THE TREATMENT OF PSORIASIS
por: Lima, Hermenio Cavalcante, et al.
Publicado: (2010)

Risankizumab: an anti-IL-23 antibody for the treatment of psoriasis
por: Haugh, Isabel M, et al.
Publicado: (2018)

Evaluation of interleukin-23 receptor (IL-23R) gene polymorphisms and serum IL-23 levels in patients with psoriasis
por: FİLİZ, Başak, et al.
Publicado: (2019)

Rationale, objectives and design of PURE, a prospective registry of patients with moderate to severe chronic plaque psoriasis in Canada and Latin America
por: Papp, Kim A., et al.
Publicado: (2019)

Compositional Alteration of Gut Microbiota in Psoriasis Treated with IL-23 and IL-17 Inhibitors
por: Huang, Yu-Huei, et al.
Publicado: (2023)

Inflammatory versus Anti-Inflammatory Profiles in Major Depressive Disorders—The Role of IL-17, IL-21, IL-23, IL-35 and Foxp3
por: Gałecka, Małgorzata, et al.
Publicado: (2021)

An Analysis of IL-10, IL-17A, IL-17RA, IL-23A and IL-23R Expression and Their Correlation with Clinical Course in Patients with Psoriasis
por: Kutwin, Magdalena, et al.
Publicado: (2021)

Psoriasis-Associated Inflammatory Conditions Induce IL-23 mRNA Expression in Normal Human Epidermal Keratinocytes
por: Kelemen, Evelyn, et al.
Publicado: (2022)

Evaluating guselkumab: an anti-IL-23 antibody for the treatment of plaque psoriasis
por: Yang, Eric J, et al.
Publicado: (2019)

Safety of selective IL‐23p19 inhibitors for the treatment of psoriasis
por: Crowley, J.J., et al.
Publicado: (2019)

A non-clinical comparative study of IL-23 antibodies in psoriasis
por: Zhou, Li, et al.
Publicado: (2021)

35181 Baseline disease and population characteristics associated with a diagnosis of COVID 19: Data from the PURE registry
por: Albrecht, Lorne, et al.
Publicado: (2022)

Apilimod Inhibits the Production of IL-12 and IL-23 and Reduces Dendritic Cell Infiltration in Psoriasis
por: Wada, Yumiko, et al.
Publicado: (2012)

IL-36 signaling in keratinocytes controls early IL-23 production in psoriasis-like dermatitis
por: Goldstein, Jérémie D, et al.
Publicado: (2020)

Drug survival of biologic therapy in a large, disease‐based registry of patients with psoriasis: results from the Psoriasis Longitudinal Assessment and Registry (PSOLAR)
por: Menter, A., et al.
Publicado: (2016)

Phosphodiesterase-4 Inhibition in Psoriasis
por: Milakovic, Milica, et al.
Publicado: (2021)

Management of scalp psoriasis: current perspectives
por: Blakely, Kim, et al.
Publicado: (2016)

Role of subnetworks mediated by [Formula: see text] , IL-23/IL-17 and IL-15 in a network involved in the pathogenesis of psoriasis
por: Pandey, Rakesh, et al.
Publicado: (2021)

Role of the IL-23/IL-17 Axis in Psoriasis and Psoriatic Arthritis: The Clinical Importance of Its Divergence in Skin and Joints
por: Boutet, Marie-Astrid, et al.
Publicado: (2018)

Skin expression of IL-23 drives the development of psoriasis and psoriatic arthritis in mice
por: Chen, Lili, et al.
Publicado: (2020)

Suppression of IL-23-mediated psoriasis-like inflammation by regulatory B cells
por: Mizumaki, Kie, et al.
Publicado: (2021)

IL-23-induced macrophage polarization and its pathological roles in mice with imiquimod-induced psoriasis
por: Hou, Yuzhu, et al.
Publicado: (2018)

Major Role of the IL17/23 Axis in Psoriasis Supports the Development of New Targeted Therapies
por: Bugaut, Hélène, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_3hk5avufrrd4m963qv8bsjtk6m